Kelly Nash, NP
Nurse Practitioner · Jackson
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 6 years
- Graduated 2020
Offices
1 location · Medical Foundation of Central Mississippi Inc · 274 clinicians in this group
Looking this up.
Hospitals listed: Mississippi Baptist Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Kelly Nash’s office at (601) 974-6246 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mississippi Baptist Medical CenterJackson, MSAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Baptist Memorial Health Care Corporation, which runs 21 hospitals in 3 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 2.43 (2.2 to 2.65), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.84 (4.24 to 7.43) · 3,474 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 4.54 (4.09 to 5) · 10,349 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.595, Oct 2024 – Sep 2025
See every measure and the patient survey for Mississippi Baptist Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 2 worse of 8 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 2.43 (2.2 to 2.65) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.84 (4.24 to 7.43) · 3,474 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 4.54 (4.09 to 5) · 10,349 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.595 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.5 to 2.05) · 2,722 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 182.45 (148.02 to 216.87) · 220 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.3 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 220 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.8 · 213 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.4 · 670 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.3 · 822 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.8 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 5,450 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.43) · 11,187 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.09 to 0.44) · 11,775 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.33 (1.02 to 3.64) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.06 (1.88 to 4.23) · 3,344 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.08 (7.76 to 16.39) · 1,426 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.42 (4.67 to 10.17) · 1,281 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.27 to 2.94) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 125 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.835 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.914 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.611 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.334 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.516 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.4 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.8 · 1,077 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.5 · 212 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 11 · 778 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.6 · 888 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 1,104 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.4 to 6.7) · 465 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.8 (6.9 to 11.4) · 465 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 131 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.8 · 97 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 455 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17) · 429 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,018 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,261 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 69% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Medicaid work
$1,192 in 2024
Medicaid paid $1,192 for 13 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 13 | $1,192 |
| 2024 | 13 | 1 | 13 | $1,192 |
| 2022 | 80 | 1 | 46 | $7,298 |
See the largest Medicaid services in earlier years
2022
| Short return visit (20+ min) | 80 | $7,298 |
Drugs they prescribed that Part D paid
$3,876
Pharmacies billed $3,876 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
96 generic and fewer than 11 brand-name prescriptions · $3,876 in drug cost · 16 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 103 | 36 | None | None | $3,876 |
| 2023 | 120 | 34 | None | None | $14,014 |
| 2022 | 371 | 120 | None | 23% | $194,822 |
| 2021 | 111 | 35 | 0% (0) | 21% | $20,638 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 8 drugs
| Xifaxan | 15 | $44,819 | $2,988 |
| Linzess | 15 | $10,437 | $696 |
| Omeprazole | 33 | $591 | $18 |
| Famotidine | 13 | $473 | $36 |
| Fluticasone Propionate | 15 | $170 | $11 |
| Atorvastatin | 12 | $133 | $11 |
| Losartan | 11 | $96 | $9 |
| Carvedilol | 11 | $94 | $9 |
Money from drug and device companies
$1,000 in 2025
| 2025 | 11 | 36 | None | $1,000 |
| 2024 | 5 | 7 | None | $195 |
| 2023 | 2 | 4 | None | $178 |
| 2022 | 6 | 14 | None | $382 |
| 2021 | 5 | 15 | None | $550 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Livdelzi | $309 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $156 | 4 payments
|
| Abbvie | Rinvoq | $108 | 6 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $107 | 5 payments
|
| Regeneron Healthcare Solutions | Dupixent | $101 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $57 | 3 payments
|
See all 36 published payments
| Madrigal Pharmaceuticals | Meals · 2025-12-03 | Rezdiffra | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-19 | Kerendia | $18 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-03 | Xifaxan | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-11-03 | Rezdiffra | $32 |
| Abbvie | Meals · 2025-10-01 | Rinvoq | $17 |
| Gilead Sciences | Meals · 2025-09-23 | None | $91 |
| Abbvie | Meals · 2025-09-09 | Rinvoq | $16 |
| Abbvie | Meals · 2025-08-25 | Rinvoq | $15 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-21 | Entyvio | $18 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-08-18 | Xifaxan | $18 |
| Madrigal Pharmaceuticals | Meals · 2025-07-14 | Rezdiffra | $28 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-13 | Eohilia | $12 |
| Celltrion USA | Meals · 2025-05-06 | Vegzelma | $24 |
| Janssen Biotech | Meals · 2025-05-05 | Tremfya | $17 |
| Regeneron Healthcare Solutions | Meals · 2025-05-01 | Dupixent | $32 |
| Abbvie | Meals · 2025-04-22 | Skyrizi | $20 |
| Janssen Biotech | Meals · 2025-04-14 | Tremfya | $19 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-04-14 | Xifaxan | $20 |
| Regeneron Healthcare Solutions | Meals · 2025-04-10 | Dupixent | $38 |
| Abbvie | Meals · 2025-04-02 | Creon | $18 |
| Celltrion USA | Meals · 2025-04-01 | Vegzelma | $16 |
| Gilead Sciences | Meals · 2025-03-20 | Epclusa | $88 |
| Phathom Pharmaceuticals | Meals · 2025-03-19 | Voquezna | $19 |
| Gilead Sciences | Meals · 2025-03-14 | None | $16 |
| Celltrion USA | Meals · 2025-03-04 | Vegzelma | $14 |
| Madrigal Pharmaceuticals | Meals · 2025-03-03 | Rezdiffra | $14 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-25 | Entyvio | $17 |
| Gilead Sciences | Meals · 2025-02-20 | Livdelzi | $92 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-17 | Kerendia | $17 |
| Novo Nordisk | Meals · 2025-02-06 | Ozempic | $17 |
| Gilead Sciences | Meals · 2025-02-05 | None | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-31 | Entyvio | $109 |
| Gilead Sciences | Meals · 2025-01-15 | None | $5 |
| Madrigal Pharmaceuticals | Meals · 2025-01-06 | Rezdiffra | $19 |
| Regeneron Healthcare Solutions | Meals · 2025-01-02 | Dupixent | $31 |
See earlier years (2024, 2023, 2022, 2021)
2024: $195
| Gilead Sciences | Livdelzi | $133 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $17 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $16 | 1 payment
|
| Amgen | Otezla | $15 | 1 payment
|
| Lilly USA | Mounjaro | $15 | 1 payment
|
2023: $178
| Gilead Sciences | None | $165 | 3 payments
|
| Phathom Pharmaceuticals | Voquezna | $13 | 1 payment
|
2022: $382
| Janssen Scientific Affairs | Stelara | $125 | 1 payment
|
| Gilead Sciences | None | $81 | 3 payments
|
| Abbvie | Mavyret | $78 | 4 payments
|
| RedHill Biopharma | Talicia | $45 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $39 | 2 payments
|
| Novo Nordisk | Saxenda | $14 | 1 payment
|
2021: $550
| AbbVie | Humira | $184 | 5 payments
|
| RedHill Biopharma | Talicia | $181 | 6 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $114 | 1 payment
|
| Gilead Sciences | None | $46 | 2 payments
|
| Braintree Laboratories | Sutab | $25 | 1 payment
|
Professional record
- NPI
- 1982200911
- Licence
- MS 904096
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 965 Ridge Lake Blvd Ste 315, Memphis, TN, 38120
- NPI first listed
- 2020-12-06
- NPI last updated
- 2024-06-05
- NPI record certified
- 2024-06-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1827 Simpson Highway 149, Mendenhall, MS, 39114 · 200 Jose Figueres Ave Ste 170, San Jose, CA, 95116
This office lists an electronic records connection.